Hikal Ltd Overview
Fundamentals of Hikal Ltd
|P/E Ratio (TTM)||55.3|
|Debt to Equity||0.66|
Financials of Hikal Ltd
|Jun 2022||Sep 2022||Dec 2022||Mar 2023|
|Profit before tax||-11.77||32.77||35.79||48.58|
|EPS in Rs||-0.72||2.01||2.14||2.92|
About Hikal Ltd
Hikal Limited, incorporated on July 08th, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and sp ... ecialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. Presently, it is operating in the crop protection and pharmaceuticals space. The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck & Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a state-of-the-art manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufacturing facility near Mumbai in collaboration with Merck & Co Inc, USA, for the manufacture of a post-harvest fungicide. It received the prestigious '5 star Safety Award' from British Safety Council' UK for high standards maintained at the Taloja Site. During 1999-2000, the company has acquired an Agrochemical manufacturing site at Panoli, Gujarat from Novartis India Limited. The Company's status as an Export House has been elevated to that of a Trading House. In 2001, it entered the pharmaceuticals business, when it acquired the R&D Unit and Bulk Drug Manufacturing Facility of Wintac Ltd at Bangalore in Karnataka. In 2004, it built a brand new API plant post-acquisition and received USFDA certification. The Bangalore API Plant approved by USFDA and Australian TGA. During 2004-05, A 100% EOU plant for pharamaceutical intermediates is being set up. This unit is expected to be operational in the first half of the coming year. During 2004-05, the company is establishing a state-of-the-art R&D facility in Pune and this research facility is expected to be operational in early 2006. In Aug. 2004, the company has entered into an agreement with Bayer CropScience AG to manufacture and supply Agro biochemical intermediates and has set up a plant to manufacture this products in Mahad Plant. In 2005, the company made an agreement with Crompton Corporation, USA to manufacture and market a New Generation Crop protection product. In Nov. 2005, the company entered into a JV agreement with a subsidiary company of Sinochem Corporation, China. During 2005-2006, the company made a strategic investment in Jiangsu Chemstar Industries Co (a subsidiary company of Sinochem Corporation China 'A Fortune 500 company). The company acquired 10% stake in the year. The companies production capacity of Crop protection products and Pharmaceutical products stood at 4436 MTn and 180 MT respectively. The Company commenced export of Gabapentine to the US and Canada markets during FY 2006-07. It acquired Marsing & Co. A/S, Denmark and commenced marketing and distribution of APIs in various countries. The Company increased investment to 16% in Jiangsu Chemstar Industries Co. Ltd., (a subsidiary company of Sinochem Corporation, China 'A FORTUNE 500' company) in FY'2007. During the year, it started supply of new Crop Protection product to one of the leading multinational companies. In Pharma plant, its existing Intermediate products registered increase in volumes and two new Pharma products were manufactured at Panoli site. R&D unit labs got upgraded and two new labs were added during the year 2007-08. In 2008, the Company established Acoris Research Ltd., a contract research facility at the International Biotech Park, Pune, which is fully operational. In 2009, it expanded manufacturing capabilities. Construction of the new multi-purpose active ingredients plant for crop protection at the Taloja site was completed. It commissioned several new multipurpose API plants at the US FDA approved site in Bangalore. It commissioned a new multipurpose pharma intermediates plant at Panoli. Long-term contracts with global life sciences companies had a substantial impact on business. It signed long-term contract for a patented molecule with a leading multinational company. As per the Scheme of Arrangement sanctioned by Order dated March 30, 2012 and approved by the Registrar of High Court Judicature of Bombay High Court, with effect from 1st April 2012, the Research and Development activity of Acoris has been demerged with Hika. Acoris formerly a subsidiary is now be a division of Hikal and has further strengthened its capabilities, both in terms of manpower as well as technical capabilities. During the year 2013, it signed a manufacturing agreement with a specialty US based food ingredient company. It completed initial supplies for advanced intermediates to one of the largest U.S. biotech companies. It signed a contract with a leading Japanese company to develop different peptides using their proprietary technology. In December 2016, Company sold its stake in subsidiary, Hikal International B.V. In 2017, it sold the R&D unit in Bangalore. The Company issued Bonus Shares on 26 June 2018 in the ratio of 1:2 i.e. one bonus equity share of Rs. 2/- each fully paid-up for every two existing equity shares of Rs. 2/- each fully paid-up held by the members. Read More
|Stocks||Market Cap (cr)||Market Price (₹)||52 Week Low-High (₹)|
|Supriya Lifescience Ltd||₹2,028.17||
|250.1 - 264.75|
|Celestial Biolabs Ltd||₹4.56||
|1.75 - 1.8|
|JFL Life Sciences Ltd||₹46.25||
|37.8 - 43|
|Procter & Gamble Health Ltd||₹8,609.84||
|5149.1 - 5219|
|Veerhealth Care Ltd||₹30.50||
|26 - 26|
What is the Share price of Hikal Ltd (HIKAL)?
Can I buy Hikal Ltd (HIKAL) shares?
How do I buy Hikal Ltd (HIKAL) from Angel One?
- Direct investment: You can buy Hikal Ltd (HIKAL) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Hikal Ltd (HIKAL) shares.
Is Hikal a Debt free Company?
No, Hikal is not a debt free company.
What is the main business of Hikal?
The main business of Hikal is to manufacture active ingredients and intermediates and offer research and development services to diverse global companies spread across sectors of pharmaceuticals, biotech, crop protection, animal health, and specialty chemicals.
Who are the promoters of Hikal?
The top promoters of Hikal are Kalyani Investment Company Limited, Shri Badrinath Investment Pvt Ltd, Shri Rameshwara Investment Pvt Ltd, Sugandha Jai Hiremath, Bf Investment Limited, Jai V Hiremath, Sameer Hiremath, Ekdant Investment Pvt Ltd, Pallavi Anish Swadi, Pallavi Trust, Sameer Trust, Sumer Trust, Rhea Trust, Ashok Vishwanath Hiremath, and Karad Engineering Consultancy Pvt Ltd.
What are the Subsidiaries that comes under Hikal?
The main subsidiaries that come under Hikal are Hikal LLC, USA and Acoris Research Limited.